Literature DB >> 12583825

Tubulin interacting agents: novel taxanes and epothilones.

Neeraj R Agrawal1, Ram Ganapathi, Tarek Mekhail.   

Abstract

The microtubule cytoskeleton plays an important part in cell mitosis, which relies on polymerization and depolymerization of the protein tubulin. Such established drugs as the vinca alkaloids and colchacine work by inhibiting microtubule assembly, as does paclitaxel. This article describes a variety of promising novel taxanes and epothilones with similar mechanisms of action that are in various states of preclinical and clinical development.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12583825     DOI： 10.1007/s11912-003-0095-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  40 in total

1.  Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines.

Authors:  H M McDaid; S K Bhattacharya; X T Chen; L He; H J Shen; C E Gutteridge; S B Horwitz; S J Danishefsky
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

2.  The action of the vincaleukolastine on mitosis in vitro.

Authors:  C G PALMER; D LIVENGOOD; A K WARREN; P J SIMPSON; I S JOHNSON
Journal:  Exp Cell Res       Date:  1960-06       Impact factor: 3.905

3.  Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules.

Authors:  Claudia J Bode; Mohan L Gupta; Emily A Reiff; Kathy A Suprenant; Gunda I Georg; Richard H Himes
Journal:  Biochemistry       Date:  2002-03-26       Impact factor: 3.162

4.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Authors:  Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

Review 5.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

6.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Authors:  M Monzó; R Rosell; J J Sánchez; J S Lee; A O'Brate; J L González-Larriba; V Alberola; J C Lorenzo; L Núñez; J Y Ro; C Martín
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

7.  Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

Authors:  K A Gelmon; J Latreille; A Tolcher; L Génier; B Fisher; D Forand; S D'Aloisio; L Vernillet; L Daigneault; A Lebecq; M Besenval; E Eisenhauer
Journal:  J Clin Oncol       Date:  2000-12-15       Impact factor: 44.544

Review 8.  Mechanisms of action and resistance to tubulin-binding agents.

Authors:  C Dumontet
Journal:  Expert Opin Investig Drugs       Date:  2000-04       Impact factor: 6.206

9.  Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

Authors:  K Bhalla; A M Ibrado; E Tourkina; C Tang; M E Mahoney; Y Huang
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

10.  Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.

Authors:  Ranjana Advani; George A Fisher; Bert L Lum; Charro Jambalos; Cheryl D Cho; Marvin Cohen; Ashwin Gollerkeri; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531
View more
  1 in total

1.  Radiosensitizing effect of epothilone B on human epithelial cancer cells.

Authors:  T Baumgart; G Klautke; S Kriesen; S A Kuznetsov; D G Weiss; R Fietkau; G Hildebrandt; K Manda
Journal:  Strahlenther Onkol       Date:  2012-01-12       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.